Novo Nordisk's Credibility Gap: When Beating Guidance Isn't Enough
Published on 08/06/2026 at 08:51 | Redaktion boerse-global.de
The arithmetic no longer adds up for Novo Nordisk investors. The Danish pharmaceutical giant delivered a second-quarter report on Tuesday that, on paper, looked like progress: adjusted revenue climbed 7 percent to 78.49 billion Danish kroner, adjusted operating profit rose 11 percent to 33.39 billion kroner, and management lifted its full-year outlook from a decline of 4 to 12 percent to a range of 0 to minus 6 percent. The stock's response? A slide of as much as 7.1 percent in Copenhagen trading on Thursday, with shares closing the week at 38.72 euros — down 13.37 percent over seven days and nearly 30 percent below their 52-week high.
The market's refusal to reward improved guidance speaks to a deeper problem: trust in the pipeline has eroded faster than the balance sheet can repair it.
A Pipeline Under Siege
The headline numbers flatter a more uncomfortable reality. Reported operating profit actually fell 16 percent, dragged down by 6.3 billion kroner in non-cash impairments. The bulk of that — 4.0 billion kroner — came from the decision to halt development of the obesity candidate Monlunabant after it showed limited efficacy and neuropsychiatric side effects. But that was only one of three setbacks to land within days of each other.
CagriSema, the next-generation weight-loss therapy, missed its primary endpoint in the Reimagine-4 study, coming up short on blood sugar control against Eli Lilly's Tirzepatil. And the Phase 3 ZEUS trial evaluating Ziltivekimab in cardiovascular and chronic kidney disease failed to hit its primary endpoint on July 31. Three failed programs in a single week is not a coincidence; it points to structural weaknesses in clinical development that a single strong quarter cannot mask.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The Pill That Can't Quite Deliver
The Wegovy pill was supposed to be the bridge between today's injectable franchise and tomorrow's pipeline. It secured European Commission approval in mid-July as the first oral GLP-1 treatment for weight reduction, and has since launched in the United Arab Emirates and the UK, with the first EU market now also live. Yet second-quarter sales of 3.2 billion kroner met analyst expectations without exceeding them — and in the current environment, meeting expectations is no longer sufficient.
The market is demanding positive surprises from Novo Nordisk, not confirmed forecasts. That shift in sentiment was underscored by Jefferies' assessment on Thursday that "many open questions for 2027" remain regarding the company's long-term competitiveness in the obesity market.
A CEO's Promise, A Sparing Program, and a Political Cloud
CEO Maziar Mike Doustdar, who took the helm relatively recently, attempted to steady nerves on Wednesday with commitments to accelerate research and pursue targeted bolt-on acquisitions to close the pipeline gap. So far, these remain intentions without named targets or timelines. The company is also still working through a cost-cutting program announced in September 2025 that will eliminate 11 percent of its global workforce — roughly 9,000 positions, including 5,000 in Denmark — a restructuring that remains a live topic nearly a year after its unveiling.
Adding to the pressure, the German government signaled earlier this week that it wants to reconsider the reimbursement status of "lifestyle medications" such as Ozempic and Wegovy. Any change to German reimbursement practice would hit Novo Nordisk in one of its most vulnerable segments.
What's Holding the Story Together
It's not all deterioration. The core business continues to grow at a double-digit profit pace, and the company raised guidance even amid the setbacks rather than cutting it. The buyback program is roughly halfway through its 15 billion kroner allocation, with 27,064,179 B-shares repurchased for 7.53 billion kroner as of August 3. An interim dividend of 3.75 kroner per share is scheduled for payment on August 18.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
There was also a legal win: a Dutch court in The Hague issued a preliminary injunction on Wednesday barring Ceban Ziekenhuisfarmacie B.V. from selling a copycat semaglutide nasal spray that allegedly infringes Novo Nordisk's supplementary protection certificate. It's a procedural victory that strengthens patent defenses, though it falls short of a final ruling.
The Valuation Question
Morningstar pegged the stock's fair value at 311 Danish kroner on Monday, following the ZEUS setback — an assessment that doesn't yet fully incorporate the quarterly report or the subsequent price action. The shares trade roughly 29 percent below their January high of 54.86 euros but have recovered substantially from the 52-week low of 30.25 euros set on March 2. Technical indicators show an RSI of 35.2, suggesting oversold conditions, though that alone rarely halts a fundamental downtrend when pipeline confidence is shaken.
The next concrete test comes on September 20, when Novo Nordisk hosts its Capital Markets Day and is expected to lay out strategy, operational direction, and financial targets in detail. That's when Doustdar's promises of accelerated research will either gain substance or remain rhetoric. Until then, the stock is likely to remain a mirror of the uncertainty — with the gap between operational improvement and investor skepticism narrower than the raised guidance would suggest.
Ad
Novo Nordisk Stock: New Analysis - 6 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
